Evidence map›Paper›PMID 29860057›Full record

Trial reportDrug and alcohol dependence2018

Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.

Marisa Briones, Steven Shoptaw, Ryan Cook, Matthew Worley, Aimee-Noelle Swanson, David E Moody, Wenfang B Fang, John Tsuang, Benjamin Furst, Keith Heinzerling

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01365819 (Varenicline for Methamphetamine Dependence), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01365819 phase2completednot on this map

Varenicline for Methamphetamine Dependence: Phase II Clinical Trial

TypeinterventionalSponsorUniversity of California, Los AngelesRan2012 to 2014Enrolled52ConditionsMethamphetamine Dependence, Substance Abuse, Methamphetamine AbuseArmsVarenicline, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marisa BrionesDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: Mbriones@mednet.ucla.edu.
Steven ShoptawDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ryan CookDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
Matthew WorleyDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Aimee-Noelle SwansonDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
David E MoodyCenter for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
Wenfang B FangCenter for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
John TsuangLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Benjamin FurstLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Keith HeinzerlingDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USHarbor–UCLA Medical Center · USUniversity of Utah · US

Funding

Varenicline for Methamphetamine DependenceR01DA030577 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2011 to 2013
$1.8M
Behavioral economic mechanisms of prescription opioid addiction in chronic painK23DA039348 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WORLEY, MATTHEW J. · 2016 to 2020
$1.0M
NIDA NIH HHS K23 DA039348NIDA NIH HHS R01 DA030577
6 · The paper itself

Abstract

backgroundPrevious studies have suggested that varenicline, an α4β2 nicotinic receptor partial agonist, and α7 nicotinic receptor full agonist, may be effective for the treatment of methamphetamine (MA) dependence due to dopaminergic effects, relief of glutamatergic and cognitive dysfunction, and activation of nicotinic cholinergic systems. This study aimed to determine if varenicline (1 mg BID) resulted in reduced methamphetamine use compared to placebo among treatment-seeking MA-dependent volunteers.

methodsTreatment-seeking MA-dependent volunteers were randomized to varenicline 1 mg twice daily (n = 27) or placebo (n = 25) and cognitive behavioral therapy for 9 weeks. The primary outcomes were the proportion of participants achieving end-of-treatment-abstinence (EOTA, MA-negative urine specimens during weeks 8 and 9) and the treatment effectiveness score (TES, number of MA-negative urine specimens) for varenicline versus placebo.

resultsThere was no significant difference in EOTA between varenicline (15%, 4/27) and placebo (20%, 5/25; p = 0.9). There was some suggestion that urinary confirmed medication compliance corresponded with EOTA in the varenicline condition, though it did not reach statistical significance, OR = 1.57 for a 100 ng/ml increase in urine varenicline, p = 0.10, 95% CI (0.99, 3.02). There was no significant difference in mean TES in the varenicline condition (8.6) compared to the placebo condition (8.1), and treatment condition was not a statistically significant predictor of TES, IRR = 1.01, p = 0.9, 95% CI (0.39, 2.70).

conclusionsThe results of this study indicate that 1 mg varenicline BID was not an effective treatment for MA dependence among treatment-seeking MA-dependent volunteers.

Indexed as

Cognitive Behavioral TherapyAdultAmphetamine-Related DisordersCombined Modality TherapyDouble-Blind MethodFemaleHumansMaleMethamphetamineNicotinic AgonistsTreatment OutcomeVareniclineMethamphetamineNicotinic AgonistsVareniclineMethamphetamine dependenceRelapseVarenicline

Identifiers

PMID29860057
PMCPMC6391991
OpenAlexW2804645708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.